QI
ENZN

Quotient Investors’s ENZON PHARMACEUTICALS INC ENZN Stock Holding History

Quotient Investors’s Portfolio ENZN Stock Details ENZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-19,670
Closed -$19K – 263
2015
Q3 		$19K Buy
+19,670
New +$24.2K ﹤0.01% 209

Other funds holding ENZN

IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
SCP
Seizert Capital Partners Birmingham, Michigan $2.42B AUM 22.12% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Quotient Investors's ENZN Position: Q4 2015 in Review

Quotient Investors sold out of ENZON PHARMACEUTICALS INC (ENZN) in Q4 2015, closing a stake of 19,670 shares — an estimated $19K sold.

Quotient Investors first reported a position in ENZN in Q3 2015 and held it in 1 quarter. The position peaked at $19K in Q3 2015. 49 funds tracked by Wall St. Rank hold ENZN as of Q4 2015.

  • Quotient Investors reported no remaining ENZON PHARMACEUTICALS INC position as of Q4 2015 after selling out during the quarter.
  • Quotient Investors sold 19,670 ENZON PHARMACEUTICALS INC shares in Q4 2015, an estimated $19K.
  • Quotient Investors first reported a position in ENZON PHARMACEUTICALS INC in Q3 2015 and held it in 1 quarter.
  • Quotient Investors's ENZON PHARMACEUTICALS INC position peaked at $19K in Q3 2015.
  • 49 funds tracked by Wall St. Rank held ENZON PHARMACEUTICALS INC as of Q4 2015.

Based on Quotient Investors's 13F filing for Q4 2015, filed 14 Jan 2016.